Skip to content

Genetic Linkage Studies of Stuttering

Genetic Studies of Stuttering

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00001604
Enrollment
3044
Registered
1999-11-04
Start date
2003-07-22
Completion date
2019-06-24
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stuttering

Keywords

DNA Samples, Stuttering, DNA Testing, Statistical Analysis, Genetic Analysis, Natural History

Brief summary

Stuttering is an abnormality in speech that affects the rhythm of speech. People who stutter know what they wish to say, but at the time are unable to say it because of involuntary repetition, unnecessary lengthening (prolongation), or early stopping (cessation). Stuttering is characterized by repetitions or prolongation of the first syllable, or silent prolongations, sometimes known as blocks. Researcher intend on studying the genetic basis for stuttering. The goal of the study is to find the genes that help cause stuttering and determine regions of the human genetic make-up (genome) that are linked to stuttering.. To do this researchers will study the patterns of inheritance in families who have had members who stutter. The study has two objectives. The first objective is to develop a large collection of DNA samples from individuals in stuttering families, that will include both members that stutter and who do not stutter. The second objective of the study will be to find out the basic combination of genes (genotype) making up all of the participants DNA. Once this is completed researchers hope to map out and find areas or regions of DNA that are linked to stuttering. Genetic linkage is the initial step in positional cloning, and the cloning of genes which predispose individuals to stuttering is a long term goal of this research study.\<TAB\>

Detailed description

A primary goal of this study is to ascertain regions of the human genome which show genetic linkage to stuttering. Genetic linkage will be determined by first obtaining genomic DNA from both affected and unaffected adults and children from families containing pairs of individuals who stutter as adults. Individuals who stutter from genetically isolated populations will also be sampled. Phenotype will be assigned by a speech-language pathologist, and DNA samples will be obtained from affected and unaffected family members from 2 cc. of saliva or from 20 cc. of blood. These DNA samples will then be genotyped using markers distributed across the human genome. The genotypic information analyzed to determine which markers or variants show linkage to stuttering. The initial goal of this study is to identify specific genetic variants, which predispose individuals to stuttering. No genetic information will be provided back to participants. A secondary goal of the study will be to perform broad clinical evaluations of the individuals found to have mutations that cause stuttering. These will take place at the NIH Clinical Center and will include standard procedures including history and physical, neurological exam, audiological exam, ophthalmologic exam, electromyographic (EMG) exam, electroencephalography (EEG), X-rays, speech evaluation, and brain imaging including MRI and fMRI.

Interventions

None listed

Sponsors

National Institute on Deafness and Other Communication Disorders (NIDCD)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: * Individuals age 8 and older. * Individuals age 6-8 with a family history of persistent stuttering * Have stuttering that persists for a period of 6 months or more or are a family member of that person * For the Phase 2 imaging studies, we will be enrolling up to 25 healthy volunteers to be controls

Exclusion criteria

* Stuttering only as a young child (before age 5) with no other family members who stutter * Inability to provide informed consent or have a parent/guardian to provide consent * Development of stuttering following trauma to the central nervous system. * Chronic medical conditions that prevent informed consent or clear evaluation of stuttering, including stroke, dementia, and degenerative neurological disease. * Inability to travel to the NIH Clinical Center for Phase 2

Design outcomes

Primary

MeasureTime frameDescription
To identify genetic mutations or variants that predispose humans to stuttering.ongoingOur primary outcome measures are the observation or exclusion of genetic linkage to stuttering at a discreet locus or genetic association with stuttering with a specific genetic variant.

Secondary

MeasureTime frameDescription
Perform clinical and physical evaluations on those individuals who stutter and possess these genetic variantsongoingdisorders in study subjects carrying genetic variants shown to be associated with stuttering in the primary outcome measures.

Countries

Japan, Pakistan, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026